DOCSLIB.ORG

Quantity Limits

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Quantity Limits Quantity Limits THERAPEUTIC CLASS PRODUCT NAME DRUG RESTRICTION TYPE PLAN LIMITS ACE INHIBITORS ACCUPRIL (QUINAPRIL HCL) TABS 5 MG, 10 MG DAILY DOSAGE 2 TABLETS PER DAY ACE INHIBITORS ACEON (PERINDOPRIL ERBUMINE) TABS 2MG, 8MG DAILY DOSAGE 2 TABLETS PER DAY ACE INHIBITORS CAPTOPRIL TABS 25 MG, 50 MG, 100 MG DAILY DOSAGE 3 TABLETS PER DAY ACE INHIBITORS MAVIK (TRANDOLAPRIL) TABS DAILY DOSAGE 2 TABLETS PER DAY ACE INHIBITORS UNIVASC (MOEXIPRIL HCL) TABS 7.5MG, 15MG DAILY DOSAGE 2 TABLETS PER DAY ACNE PRODUCTS ABSORICA CAPS DAILY DOSAGE 2 CAPSULES PER DAY ACNE PRODUCTS ACZONE (DAPSONE) 5% GEL TOPICAL DOSE LIMIT 1 TUBE PER FILL AMNESTEEM, CLARAVIS, MYORISAN, ZENATANE ACNE PRODUCTS (ISOTRETINOIN) CAPS DAILY DOSAGE 2 CAPSULES PER DAY ACNE PRODUCTS AZELEX 20% CREAM TOPICAL DOSE LIMIT 50 GRAMS PER 30 DAYS ACNE PRODUCTS CLEOCIN (CLINDAMYCIN PHOSPHATE) SOLN 1% TOPICAL DOSE LIMIT 60 ML PER 30 DAYS ACNE PRODUCTS DIFFERIN (ADAPALENE ) 0.1% LOTION TOPICAL DOSE LIMIT 59 ML PER 30 DAYS ACNE PRODUCTS DIFFERIN (ADAPALENE) 0.1% CREAM, 0.3% GEL TOPICAL DOSE LIMIT 45 GRAMS PER 30 DAYS ACNE PRODUCTS EPIDUO FORTE GEL TOPICAL DOSE LIMIT 45 GRAMS PER 30 DAYS ACNE PRODUCTS FABIOR 0.1% FOAM TOPICAL DOSE LIMIT 100 GRAMS PER 30 DAYS ACNE PRODUCTS KLARON (SULFACETAMIDE SODIUM 10% ) LOTION TOPICAL DOSE LIMIT 120 ML PER 10 DAYS ACNE PRODUCTS RETIN-A MICRO 0.06% MICROSPHERE GEL TOPICAL DOSE LIMIT 50 GRAMS PER FILL ACNE PRODUCTS ZIANA (CLINDAMYCIN PHOSPHATE-TRETINOIN) GEL TOPICAL DOSE LIMIT 1 TUBE PER FILL QUANTITY LIMIT 1 GRAM PER DAY AGENTS FOR EXTERNAL WARTS VEREGEN OINTMENT FILL FREQUENCY 120 GRAMS PER 365 DAYS AGENTS FOR GAUCHER DISEASE ZAVESCA (MIGLUSTAT ) CAPS DAILY DOSAGE 3 CAPSULES PER DAY ALLERGEN EXTRACTS ORALAIR DAILY DOSAGE 1 TABLET PER DAY ALPHA-2 RECEPTOR ANTAGONISTS REMERON (MIRTAZAPINE) TABS 15 MG, 7.5 MG DAILY DOSAGE 2 TABLETS PER DAY ALPHA-2 RECEPTOR ANTAGONISTS REMERON (MIRTAZAPINE) TABS 30 MG, 45 MG DAILY DOSAGE 1 TABLET PER DAY REMERON SOLTAB (MIRTAZAPINE) ORAL DISINTEGRATING 15 ALPHA-2 RECEPTOR ANTAGONISTS MG DAILY DOSAGE 2 TABLETS PER DAY REMERON SOLTAB (MIRTAZAPINE) ORAL DISINTEGRATING 30 ALPHA-2 RECEPTOR ANTAGONISTS MG, 45 MG DAILY DOSAGE 1 TABLET PER DAY COREG (CARVEDILOL) CR 24 HOUR CAPSULES 10MG, 20MG, ALPHA-BETA BLOCKERS 40MG DAILY DOSAGE 2 CAPSULES PER DAY ALPHA-BETA BLOCKERS COREG (CARVEDILOL) CR 24 HOUR CAPSULES 80 MG DAILY DOSAGE 1 CAPSULE PER DAY ALPHA-BETA BLOCKERS LABETALOL HCL TABS 300 MG DAILY DOSAGE 8 TABLETS PER DAY ALPHA-GLUCOSIDASE INHIBITORS GLYSET (MIGLITOL) TABS DAILY DOSAGE 3 TABLETS PER DAY AMINOGLYCOSIDES BETHKIS (TOBRAMYCIN) NEBULIZED SOLUTION INHALATION DOSE LIMIT 4 DOSES PER DAY AMINOGLYCOSIDES KITABIS (TOBRAMYCIN) PAK NEBULIZED SOLUTION INHALATION DOSE LIMIT 280 ML PER 56 DAYS AMINOGLYCOSIDES TOBI (TOBRAMYCIN) NEBULIZED SOLUTION INHALATION DOSE LIMIT 280 ML PER 56 DAYS AMINOGLYCOSIDES TOBI PODHALER CAPS INHALATION DOSE LIMIT 4 DOSES PER DAY ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 10 AMPHETAMINES MG DAILY DOSAGE 4 TABLETS PER DAY SHP_20173926 Quantity Limits THERAPEUTIC CLASS PRODUCT NAME DRUG RESTRICTION TYPE PLAN LIMITS ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 12.5 AMPHETAMINES MG DAILY DOSAGE 4 TABLETS PER DAY ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 15 AMPHETAMINES MG DAILY DOSAGE 4 TABLETS PER DAY ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 20 AMPHETAMINES MG DAILY DOSAGE 3 TABLETS PER DAY ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 30 AMPHETAMINES MG DAILY DOSAGE 2 TABLETS PER DAY AMPHETAMINES ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 5 MG DAILY DOSAGE 8 TABLETS PER DAY ADDERALL (AMPHETAMINE-DEXTROAMPHETAMINE) TABS 7.5 AMPHETAMINES MG DAILY DOSAGE 2 TABLETS PER DAY ADDERALL XR (AMPHETAMINE-DEXTROAMPHETAMINE) AMPHETAMINES 24 HOUR CAPS 15MG DAILY DOSAGE 4 CAPSULES PER DAY ADDERALL XR (AMPHETAMINE-DEXTROAMPHETAMINE) AMPHETAMINES 24 HOUR CAPS 20 MG DAILY DOSAGE 3 CAPSULES PER DAY ADDERALL XR (AMPHETAMINE-DEXTROAMPHETAMINE) AMPHETAMINES 24 HOUR CAPS 25 MG DAILY DOSAGE 2 CAPSULES PER DAY ADDERALL XR (AMPHETAMINE-DEXTROAMPHETAMINE) AMPHETAMINES 24 HOUR CAPS 30 MG DAILY DOSAGE 2 CAPSULES PER DAY ADDERALL XR (AMPHETAMINE-DEXTROAMPHETAMINE) AMPHETAMINES 24 HOUR CAPS 5 MG, 10 MG DAILY DOSAGE 2 CAPSULES PER DAY AMPHETAMINES DESOXYN (METHAMPHETAMINE HCL) TABS DAILY DOSAGE 5 TABLETS PER DAY DEXEDRINE (DEXTROAMPHETAMINE SULFATE) CAPS 24 HOUR AMPHETAMINES 5MG, 10MG, 15MG DAILY DOSAGE 4 CAPSULES PER DAY AMPHETAMINES PROCENTRA (DEXTROAMPHETAMINE SULFATE) SOLN 5 MG/5ML ORAL DOSE LIMIT 60 ML PER DAY AMPHETAMINES VYVANSE CAPS - ALL STRENGTHS DAILY DOSAGE 1 CAPSULE PER DAY AMPHETAMINES VYVANSE CHEW 10 MG, 20 MG, 30 MG, 40 MG, 50 MG, 60 MG DAILY DOSAGE 1 TABLET PER DAY AMPHETAMINES ZENZEDI (DEXTROAMPHETAMINE SULFATE) TABS 10 MG DAILY DOSAGE 6 TABLETS PER DAY AMPHETAMINES ZENZEDI (DEXTROAMPHETAMINE SULFATE) TABS 5 MG DAILY DOSAGE 8 TABLETS PER DAY QUANTITY LIMIT 2 FILLS PER 365 DAYS; ANALEPTICS CAFFEINE CITRATE SOLN ORAL FILL FREQUENCY 45ML PER 15 DAYS RETAIL ESGIC (BUTALBITAL-ACETAMINOPHEN-CAFFEINE) CAPS 325MG- ANALGESIC COMBINATIONS 50MG-40MG DAILY DOSAGE 4 CAPSULES PER DAY ANALGESIC COMBINATIONS FIORINAL (BUTALBITAL-ASPIRIN-CAFFEINE) CAPS DAILY DOSAGE 4 CAPSULES PER DAY EPINEPHRINE (ANAPHYLAXIS) SOLN AUTO INJECTOR QUANTITY LIMIT 2 DEVICES PER 30 DAYS ANAPHYLAXIS THERAPY AGENTS 0.15 MG/0.3ML, 0.3 MG/0.3ML FILL FREQUENCY 4 DEVICES PER 365 DAYS QUANTITY LIMIT 2 DEVICES PER 30 DAYS ANAPHYLAXIS THERAPY AGENTS EPIPEN 2-PAK SOLN AUTO INJECTOR FILL FREQUENCY 4 DEVICES PER 365 DAYS QUANTITY LIMIT 2 DEVICES PER 30 DAYS ANAPHYLAXIS THERAPY AGENTS EPIPEN-JR 2-PAK SOLN AUTO INJECTOR FILL FREQUENCY 4 DEVICES PER 365 DAYS SHP_20173926 Quantity Limits THERAPEUTIC CLASS PRODUCT NAME DRUG RESTRICTION TYPE PLAN LIMITS ANDROGENS ANDRODERM PATCH 24 HOUR, 2MG/24HR, 4MG/24HR TOPICAL DOSE LIMIT 1 PATCH PER DAY ANDROGEL (TESTOSTERONE) TRANSDERMAL TOPICAL GEL 1% ANDROGENS 2.5 GRAM PACKET TOPICAL DOSE LIMIT 150 GRAMS PER 30 DAYS ANDROGEL (TESTOSTERONE)TRANSDERMAL TOPICAL GEL ANDROGENS 1.62%, PACKETS, PUMP TOPICAL DOSE LIMIT 2 BOXES PER 30 DAYS ANDROGENS AXIRON (TESTOSTERONE) TRANSDERMAL TOPICAL SOLUTION TOPICAL DOSE LIMIT 180ML PER 30 DAYS DEPO-TESTOSTERONE (TESTOSTERONE CYPIONATE) INJ ANDROGENS 200MG/ML FILL FREQUENCY 1 FILL PER 30 DAYS TESTIM (TESTOSTERONE) TRANSDERMAL TOPICAL GEL 1% 5 ANDROGENS GRAM PACKET TOPICAL DOSE LIMIT 300 GRAMS PER 30 DAYS ANDROGENS VOGELXO (TESTOSTERONE) 1% TRANSDERMAL PUMP TOPICAL DOSE LIMIT 150 GRAMS PER 30 DAYS ANESTHETICS TOPICAL ORAL LIDOCAINE HCL (MOUTH-THROAT) SOLN ORAL DOSE LIMIT 100 ML PER 10 DAYS ANGIOTENSIN II RECEPTOR ANTAGONISTS ATACAND (CANDESARTAN CILEXETIL) TABS 32 MG DAILY DOSAGE 1 TABLET PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS ATACAND (CANDESARTAN CILEXETIL) TABS 4 MG, 8 MG, 16 MG DAILY DOSAGE 2 TABLETS PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS BENICAR (OLMESARTAN MEDOXOMIL) 40 MG TABS DAILY DOSAGE 1 TABLET PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS BENICAR (OLMESARTAN MEDOXOMIL) 5MG, 20MG TABS DAILY DOSAGE 2 TABLETS PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS DIOVAN (VALSARTAN) TABS 40 MG, 80 MG, 160 MG, 320 MG DAILY DOSAGE 1 TABLET PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS EDARBI (AZILSARTAN MEDOXOMIL) TABS 40MG, 80MG DAILY DOSAGE 1 TABLET PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS EPROSARTAN MESYLATE TABS DAILY DOSAGE 1 TABLET PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS MICARDIS (TELMISARTAN) TABS 40MG DAILY DOSAGE 2 TABLETS PER DAY ANGIOTENSIN II RECEPTOR ANTAGONISTS MICARDIS (TELMISARTAN) TABS 80MG DAILY DOSAGE 1 TABLET PER DAY QUANTITY LIMIT ANTACIDS CALCIUM CARBONATE SUSPENSION 1250ML/5ML FILL FREQUENCY 500 ML PER 30 DAYS ANTIADRENERGIC ANTIHYPERTENSIVES CATAPRES-TTS-1 PTWK (CLONIDINE HCL) TOPICAL DOSE LIMIT 4 PATCHES PER 28 DAYS ANTIADRENERGIC ANTIHYPERTENSIVES CATAPRES-TTS-2 PTWK (CLONIDINE HCL) TOPICAL DOSE LIMIT 4 PATCHES PER 28 DAYS ANTIADRENERGIC ANTIHYPERTENSIVES CATAPRES-TTS-3 PTWK (CLONIDINE HCL) TOPICAL DOSE LIMIT 4 PATCHES PER 28 DAYS ANTIADRENERGIC ANTIHYPERTENSIVES RESERPINE 0.1MG TABS DAILY DOSAGE 1 TABLET PER DAY ANTIADRENERGIC ANTIHYPERTENSIVES RESERPINE 0.25MG TABS DAILY DOSAGE 4 TABLETS PER DAY SHP_20173926 Quantity Limits THERAPEUTIC CLASS PRODUCT NAME DRUG RESTRICTION TYPE PLAN LIMITS BUSPAR (BUSPIRONE HCL) TABS 5 MG, 10 MG, 15 MG, 30 MG, 7.5 ANTIANXIETY AGENTS - MISC. MG DAILY DOSAGE 3 TABLETS PER DAY ANTICATAPLECTIC AGENTS XYREM SOLUTION ORAL DOSE LIMIT 18 ML PER DAY ANTICONVULSANTS - CLONAZEPAM-ODT ORAL DISINTEGRATING TABLETS BENZODIAZEPINES 0.125 MG, 0.25 MG, 0.5 MG, 1 MG, 2 MG DAILY DOSAGE 4 TABLETS PER DAY ANTICONVULSANTS - BENZODIAZEPINES DIASTAT (DIAZEPAM) ACUDIAL RECTAL GEL 10 MG TOPICAL DOSE LIMIT 4 DOSES PER 30 DAYS ANTICONVULSANTS - QUANTITY LIMIT BENZODIAZEPINES DIASTAT (DIAZEPAM) ACUDIAL RECTAL GEL 20 MG FILL FREQUENCY 8 DOSES PER 30 DAYS ANTICONVULSANTS - BENZODIAZEPINES DIASTAT (DIAZEPAM) PEDIATRIC RECTAL GEL 2.5MG FILL FREQUENCY 1 KIT PER FILL ANTICONVULSANTS - BENZODIAZEPINES KLONOPIN (CLONAZEPAM) TABS 0.5 MG, 1 MG, 2 MG DAILY DOSAGE 4 TABLETS PER DAY ANTICONVULSANTS - BENZODIAZEPINES NAYZILAM SPRAY TOPICAL DOSE LIMIT 10 DOSES PER 30 DAYS ANTICONVULSANTS - BENZODIAZEPINES ONFI (CLOBAZAM) SUSP 2.5MG/ML ORAL DOSE LIMIT 16ML PER DAY ANTICONVULSANTS - BENZODIAZEPINES ONFI (CLOBAZAM) TABS 10 MG DAILY DOSAGE 3 TABLETS PER DAY ANTICONVULSANTS - BENZODIAZEPINES ONFI (CLOBAZAM) TABS 20 MG DAILY DOSAGE 2 TABLETS PER DAY ANTICONVULSANTS - MISC. APTIOM TABS 200MG, 400MG DAILY DOSAGE 1 TABLET PER DAY ANTICONVULSANTS - MISC. APTIOM TABS 600MG, 800MG DAILY DOSAGE 2 TABLETS PER DAY ANTICONVULSANTS - MISC. BANZEL SUSP 40 MG/ML ORAL DOSE
Load more

Recommended publications
  • The Experience We Bring to You, Matters to TOM
    The experience we bring to you, matters to TOM From the first automatic lancing device to our patented self-injection devices, with Owen Mumford you have access to unrivalled experience in designing, developing and delivering solutions to help make adherence easier for your patients...just like Tom. PUTTING LIFE INTO TECHNOLOGY Proven design Proven devices: self-injection Ensuring that patients are willing and able to inject their medication is key to their wellbeing and Innovation derived from 6 decades of collective your success. As pioneers in both auto-injectors and self-injection pens, our experience has design and engineering experience helped seven out of ten leading pharmaceutical companies find the solution that is right for them. The Autopen® family of platform solutions Proven development Autopen®1 The first injection pen with side-button automatic delivery A fully integrated approach with seamless ® Autopen®1’s side mounted push-button is designed Autopen 2 support from start to finish to be less intimidating than a plunger and easier to The injector pen with increased dose control handle, even for people with smaller hands or reduced As with the original Autopen®1, Autopen®2 is ® dexterity. The Autopen 1 platform has been trusted an easy-to-use and durable device, but it was by 2/3 of the largest insulin suppliers, and in treating created with a click-back function to correct Growth Hormone Deficiency, Infertility, Osteoporosis, over-dialling prior to injection, overcoming some Proven delivery and Multiple Sclerosis and veterinary applications. of the barriers patients face when self-injecting. In-market success assured by an unparalleled track-record Autopen®3 The disposable self-injection pen with automatic push-button delivery Autopen®3 provides all the benefits of an automatic delivery device along with the added convenience of an injection pause function.
    [Show full text]
  • Flexrx Standard Prior Authorization, Quantity Limit, and Step Therapy Drug List
    FlexRx Standard Prior Authorization, Quantity Limit, and Step Therapy Drug List How to use this drug list This drug list includes drugs that have a prior authorization (PA) requirement, a quantity limitation (QL), or a step therapy (ST) requirement. For additional information about the various drug programs, you can refer to Bluecrossmn.com. This information is subject to change. Generic drugs are listed in lowercase boldface (e.g., rabeprazole) Brand name drugs are capitalized (e.g., ACIPHEX) Acronyms PA = Prior Authorization, QL = Quantity Limit per 30 days, ST = Step Therapy Program *Unless otherwise noted, prior authorization program and quantity limits applies to both brand and generic. These programs and quantity limitations may not apply. Check your certificate or other plan information for benefit details. BRAND NAME (generic name - if available) Requirement Quantity Limits per 30 days± ABILIFY MAINTENA QL 1 vial/4 weeks ABILIFY tabs (aripiprazole) QL ST* 30 tabs ABSTRAL PA QL 120 tabs ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE QL 300 caps or tabs acetaminophen/codeine solution, 120-12 mg/5 mL QL 2700 mL ACIPHEX (rabeprazole) 20 mg tab QL ST* 30 tabs ACIPHEX sprinkle QL ST 30 caps ACTEMRA QL ST 4 syringes/28 days ACTICLATE (doxycycline hyclate) PA ACTIQ (fentanyl citrate lozenge on a handle) PA QL 120 lozenges ACTONEL (risedronate) 150 mg QL 1 tab ACTONEL (risedronate) 35 mg QL 4 tabs/28 days ACTONEL (risedronate) 5 mg, 30 mg QL 30 tabs ADCIRCA PA** QL 60 tabs ADDERALL (amphetamine/dextroamphetamine) 20 mg QL 90 tabs ADDERALL (amphetamine/dextroamphetamine)
    [Show full text]
  • General Medical Treatment and First
    5.9 FIRST AID AND GENERAL MEDICAL TREATMENT Aim The excellent care of the children at The Downs is a vital aspect of the school, indeed the safety, health and welfare of the pupils, including those in Early Years (EYFS), and its employees is a priority of the School. This policy is drawn up under reference to the DfE ‘Guidance on First Aid’ and ‘Guidance on the use of adrenaline auto-injectors in schools’. Objectives To make appropriate First Aid available to all members of the community as quickly and efficiently as is possible. To ensure that the Matrons and other members of staff are suitably qualified First Aiders. In regard to EYFS this will mean Paediatric training - First Aid is provided by competent adults. To ensure the appropriate medical resources are available as necessary To ensure the proper and effective keeping of records Matrons The Matrons at The Downs are responsible for the medical care of the children. The Matron’s are based in the Medical Room. This is in Charlton House at the top of the stairs. The department’s facilities also include a Sick Bay for those who need to go to bed. There are four Matrons, a least one being on duty at all times. The Matrons are all First Aid qualified, but it is often the case that they have worked in the nursing profession. They administer first aid, deal with accidents or emergencies and provide care if someone is taken ill. Many members of the teaching staff are also trained and qualified as First Aiders.
    [Show full text]
  • Adverse Events: the Role of Formulations and Delivery Systems
    12 Adverse events: the role of formulations and delivery systems 12.1 Introduction 482 12.11 Reactions to impurities 494 12.2 Excipient effects 483 12.12 Crystallisation 503 12.3 E-numbers 485 12.13 Abnormal bioavailability and adverse events 504 12.4 Cross-reactivity of drugs 487 12.14 Photochemical reactions and 12.5 Non-ionic surfactants 487 photoinduced reactions 506 12.6 Polyoxyethylene glycols 488 12.15 Conclusions 509 12.7 Adjuvants as therapeutic substances 488 References 510 12.8 Active excipients in multiple therapies 490 Further reading 511 12.9 Influence of dosage form type 491 12.10 Tear films and eye drops 492 The main purpose of formulations is to deliver active substances in accurate doses in medicines that are stable and of a high and consistent quality. Drugs are often the smallest proportion of a medicine, and the variety of other ingredients within most dose forms is large. Some of these excipients serve more than one purpose and some have some biological activity. The reason we discuss in this textbook adverse events which may follow from administration of medicines is that some of the problems that arise are the result of excipients interacting physically or chemically with drugs or with themselves, or creating instability or, in some instances, having biological activity of their own. That activity may not be a direct pharmacological or toxicological action, though some agents, such as some non-ionic surfactants, may cause anaphylactic responses or affect drug absorption rates and extent by solubilisation effects or by acting on P-glycoprotein receptors, thus influencing bioavailability.
    [Show full text]
  • Antares Pharma, Inc
    Antares Pharma, Inc. Annual Report 2018 Form 10-K (NASDAQ:ATRS) Published: March 13th, 2018 PDF generated by stocklight.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15 (D) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission file number 1-32302 ANTARES PHARMA, INC. (Exact name of registrant as specified in its charter) A Delaware corporation I.R.S. Employer Identification No. 41-1350192 100 Princeton South, Suite 300, Ewing, NJ 08628 Registrant’s telephone number, including area code: (609) 359-3020 Securities registered pursuant to section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock NASDAQ Capital Market Securities registered pursuant to section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. YES ☐ NO ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Additional Support for Managing Your Child's Asthma Children's
    Children’s Community Nursing Team The Poynt 2-4 Poynters Road Luton. LU4 0LA Tel: 0333 405 0079 Email: [email protected] (non-urgent queries) Additional support for managing your Search for: ‘cypluton.asthma’ (Instagram) child’s Asthma Information for parents, carers and patients 'Please remember to take your salbutamol (blue inhaler) and spacer with you at all times in case of an emergency. Children’s Community Nursing Team Also take all medication, including spacer, to any GP/Hospital appointment. Remember to attend your asthma checks with your GP. 0682 - Jan 2020 (V1) Jan 2020 Jan 2023 When I have an asthma attack This information booklet is to help you manage you/your child’s asthma. I’m having an asthma attack if: Common Triggers My blue reliever inhaler isn’t helping, or Aerosols – Please avoid using aerosols around your child I can’t walk or talk easily, or Animal Dander – Avoid our furry friends as much as possible, if not I’m breathing hard and fast, or possible please ensure that you have an anti-histamine e.g. Piriton®, salbutamol (blue inhaler) and spacer available at all times. I’m coughing or wheezing a lot. Cigarette Smoke – Smoking permanently damages the airways; this includes second hand smoke. Please do not smoke cigarettes around When I have an asthma attack, I should: your child and remember that the harmful chemicals cling to clothing and skin for at least 2 hours after smoking. Sit up – don’t lie down. Try to be calm. Chemicals (bleach, chlorine, paint etc.) – ensure good ventilation if Take my blue inhaler and have using chemicals 10 puffs; (via a spacer).
    [Show full text]
  • The Device Side of Combination Products Technical and Regulatory Challenges in Life Cycle Management
    The Device Side of Combination Products Technical and Regulatory Challenges in Life Cycle Management Bob Laughner Associate Director, Combination Products 04 May 2016 What are combination products? Combination Product Combination products are the combination of two or more regulated entities (e.g. drug/device, biologic/device). Each entity (constituent part) contributes one or more mode of action to the final product. Example: Prefilled syringe has at least two modes of action • Syringe = subcutaneous injection • Medication = pharmaceutical action A CP is generally approved by a regulator based on its primary mode of action (i.e. the mode that contributes the most important therapeutic effect) 3 Combination Product Types There are three types of combination products: 1. Single-entity (e.g. integral) 2. Co-packaged (e.g. kits) 3. Cross-labeled (e.g. virtual) 4 Combination Product Types Single-entity (e.g. integral) examples: • Prefilled drug delivery systems – Prefilled syringes – Prefilled autoinjectors – Prefilled pen injectors – Prefilled on-body delivery systems – Dry-powder inhalers – Metered dose inhalers – Prefilled nasal sprayers – Transdermal patches – Iontophoretic delivery systems 5 Combination Product Types Single-entity (e.g. integral) examples (cont.): • Medicated devices – Drug-coated stents – Drug-coated catheters – Drug-coated pacemaker leads – Antimicrobial surgical scrubs – Antimicrobial wound dressings – Antibiotic-impregnated surgical mesh – Antibiotic bone cements – Spermicidal condoms 6 Combination Product Types Co-packaged (e.g. kits) examples: • Convenience kits – Surgical trays with anesthetic and/or surgical scrub – Vial and syringe packs – Injector pen with user-loaded prefilled cartridge – Liquid medication with dose-dispenser • Other – Collagen sponge with bone morphogenic protein 7 Combination Product Types Co-labeled (e.g.
    [Show full text]
  • 1 Basic Concepts in Medication Administration
    00Hargrave(F)-FM 11/11/07 3:15 PM Page i Pharmacology Success A Course Review Applying Critical Thinking to Test Taking 00Hargrave(F)-FM 11/11/07 3:15 PM Page ii 00Hargrave(F)-FM 11/11/07 3:15 PM Page iii Pharmacology Success A Course Review Applying Critical Thinking to Test Taking Ray A. Hargrove-Huttel RN, PhD Trinity Valley Community College Kaufman, Texas Kathryn Cadenhead Colgrove RN, MS, CNS, OCN Trinity Valley Community College Kaufman, Texas 00Hargrave(F)-FM 11/11/07 3:15 PM Page iv F. A. Davis Company 1915 Arch Street Philadelphia, PA 19103 www.fadavis.com Copyright © 2008 by F. A. Davis Company Copyright © 2008 by F. A. Davis Company. All rights reserved. This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America Last digit indicates print number: 10 9 8 7 6 5 4 3 2 1 Publisher, Nursing: Robert G. Martone Director of Content Development: Darlene D. Pedersen Project Editor: Padraic J. Maroney Art and Design Manager: Carolyn O’Brien As new scientific information becomes available through basic and clinical research, recommended treatments and drug therapies undergo changes. The author(s) and publisher have done everything possible to make this book accurate, up to date, and in accord with accepted standards at the time of publication. The author(s), editors, and publisher are not responsible for errors or omissions or for consequences from application of the book, and make no warranty, expressed or implied, in regard to the contents of the book.
    [Show full text]
  • LCMS-9030Liquid Chromatograph Mass Spectrometer
    JUNE 2019 Volume 31 Number 6 BRAT LE IN E G C A N Y N R IVERSA Bringing Drug Delivery Home FOR PERSONAL, NON-COMMERCIALto Patients USE FORMULATION PEER-REVIEW ANALYTICS Solubility and Bioavailability Managing Raw Data Glycosylation for Biopharma Quadrupole Time-of-Flight LCMS-9030Liquid Chromatograph Mass Spectrometer FOR PERSONAL, NON-COMMERCIAL USE Effortless performance The LCMS-9030 quadrupole time-of-flight (Q-TOF) mass Effortless performance spectrometer integrates the world’s fastest and most with less recalibration and easy switching between sensitive quadrupole technology with TOF architecture. ionization units It delivers high resolution accurate-mass detection with incredibly fast data acquisition for routine applications. Small footprint due to a simple and compact floor-standing design Greater accuracy and higher sensitivity based on patented Ultra-Fast technologies Identify and quantify more compounds with greater confidence in food applications, forensics, drug identification, proteomics and metabolomics www.shimadzu.eu/effortless-performance June 2019 Pharmaceutical Technology Europe is the authoritative Advancing Development & Manufacturing source of peer-reviewed research and expert analyses for scientists, engineers, and managers engaged in process PharmTech.com development, manufacturing, formulation and drug delivery, API synthesis, analytical technology and testing, packaging, IT, outsourcing, and regulatory compliance Cover: daniilantiq2010/ in the pharmaceutical and biotechnology industries. Sylfida - stock.adobe.com Art direction: Dan Ward 13 26 9 38 PharmTech.com GOOD LABORATORY PRACTICES Features 31 Good Laboratory Practices: Getting on the Same Page Quality and compliance depend on the right approaches COVER STORY to training, standard operating procedures, and validation. 9 Bringing Drug Delivery Home to Patients More tools are available to help ensure success.
    [Show full text]
  • Quantity Limits
    Quantity Limits THERAPEUTIC CLASS PRODUCT NAME DRUG RESTRICTION TYPE PLAN LIMITS ACE INHIBITORS ACCUPRIL (QUINAPRIL HCL) TABS 5 MG, 10 MG DAILY DOSAGE 2 TABLETS PER DAY ACE INHIBITORS ACEON (PERINDOPRIL ERBUMINE) TABS 2MG, 8MG DAILY DOSAGE 2 TABLETS PER DAY ACE INHIBITORS CAPTOPRIL TABS 25 MG, 50 MG, 100 MG DAILY DOSAGE 3 TABLETS PER DAY ACE INHIBITORS MAVIK (TRANDOLAPRIL) TABS DAILY DOSAGE 2 TABLETS PER DAY ACE INHIBITORS UNIVASC (MOEXIPRIL HCL) TABS 7.5MG, 15MG DAILY DOSAGE 2 TABLETS PER DAY ACNE PRODUCTS ABSORICA CAPS DAILY DOSAGE 2 CAPSULES PER DAY ACNE PRODUCTS ACANYA (CLINDAMCYIN-BENZOYL PEROXIDE) GEL TOPICAL DOSE LIMIT 1.7 GRAMS PER DAY ACNE PRODUCTS ACZONE (DAPSONE) 5% GEL TOPICAL DOSE LIMIT 1 TUBE PER FILL ACNE PRODUCTS ACZONE (DAPSONE) 7.5% GEL TOPICAL DOSE LIMIT 3 GRAMS PER DAY ACNE PRODUCTS ALTRENO (TRETINOIN) LOTION 0.05% TOPICAL DOSE LIMIT 1.5 GRAMS PER DAY AMNESTEEM, CLARAVIS, MYORISAN, ZENATANE ACNE PRODUCTS DAILY DOSAGE 2 CAPSULES PER DAY (ISOTRETINOIN) CAPS ACNE PRODUCTS AMZEEQ (MINOCYCLINE FOAM 4%) TOPICAL DOSE LIMIT 1 GRAM PER DAY ACNE PRODUCTS ARAZLO LOTION 0.045% TOPICAL DOSE LIMIT 45 GRAMS PER 30 DAYS ACNE PRODUCTS ATRALIN (TRETINOIN) GEL 0.05% TOPICAL DOSE LIMIT 1.5 GRAMS PER DAY ACNE PRODUCTS AZELEX 20% CREAM TOPICAL DOSE LIMIT 50 GRAMS PER 30 DAYS ACNE PRODUCTS BENZOYL PEROXIDE GEL 5% TOPICAL DOSE LIMIT 3 GRAMS PER DAY ACNE PRODUCTS CLEOCIN (CLINDAMYCIN PHOSPHATE) SOLN 1% TOPICAL DOSE LIMIT 60 ML PER 30 DAYS ACNE PRODUCTS CLEOCIN (CLINDAMYCIN PHOSPHATE) GEL 1% TOPICAL DOSE LIMIT 75 GRAMS PER 30 DAYS ACNE PRODUCTS
    [Show full text]
  • Drug Delivery Devices - Does the Toolkit Need Changing?
    Drug delivery devices - does the toolkit need changing? Getting drugs into the body to the target organs and tissues is not always easy. The concept of the swallowable pill that can survive the hostile conditions of the human digestive tract and yield its payload throughout the body at safe and efficacious levels is an ideal that cannot always be realized. Instead, over the last century, a range of devices has So is the toolkit good enough or does it need to evolved which are designed to deliver pharmaceutical change? Whatever your views are on the subject, ingredients more precisely, overcoming natural barriers there are signs that the industry is waking up to the and avoiding the body’s defences. So, in the standard possibility of some radical new approaches to drug drug developer’s toolkit, we have the hypodermic delivery, driven by a number of specific needs. Here needle syringe and its close relatives the injector pen are four examples of recent additions to the delivery and autoinjector for percutaneous delivery into dermis, toolkit: muscle and bloodstream. Alongside these are the inhalers: some relatively simple, like the pressurised Wearables metered dose inhalers; and some more complicated, Wearable drug pumps have been around for a while, such as breath-actuated dry powder inhalers, all of but they are getting more sophisticated, less obtrusive which are designed to send drugs to the lungs without and are now delivering drugs other than insulin. Take premature deposition en route. And for those more for example Chrono Therapeutics’ cigarette smoking specialised applications, the toolkit contains such cessation aid.
    [Show full text]
  • Self-Injection Technology and Trends
    IPT 20 2006 31/8/06 09:13 Page 60 Drug Delivery & Formulations Self-Injection Technology and Trends Modern-day self-injection devices incorporate a number of advanced features which makes them more acceptable to patients, thereby saving on healthcare resources and costs. By Ian Thompson at Ypsomed Ian Thompson is Manager, Business Development, at Ypsomed AG, where he has been working for the last 10 years with pharma and biotech partners to develop and bring to market innovative and reliable injection systems for self-administration. Ian has 20 years’ experience in the selling and marketing of technical products, the last 14 of which have been spent in the field of medical devices. He has a degree in Biochemistry, a Masters in Biotechnology and an MBA from Henley Management College, UK Self-injection technology has come a long way since pen injector. Pen injectors are essentially sophisticated the first devices were introduced in the early 1980s. syringes and were developed for the reliable and accurate Prefilled syringes are becoming more popular for self-administration of the first wave of biotech self-injection, and auto-injectors are helping to molecules, such as insulin and human growth hormone simplify their use in both existing and new (hGH). Auto-injectors have been on the market as long therapeutic areas. This article will review the as pen injectors but, until the 1990s, their use was development of self-injection technology over the restricted to emergency situations such as epinephrine years and examine some of the key features for treating anaphylactic shock (EpiPen®). The first incorporated into modern-day devices, as well as prefilled syringe-based reusable auto-injector came in possible future developments.
    [Show full text]